Video

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Daniel J. George, MD, professor of medicine, professor in surgery, Duke Cancer Institute, discusses the importance of understanding mutations in prostate cancer.

The treatment landscape for patients with prostate cancer continues to change due to multiple factors, Goerge said. These changes can be attributed to the recognition that it’s not a monolithic disease, George adds. Prostate cancer is comprised of different subsets which can be defined by the genetic makeup of these cancers, George explains.

Moreover, the genetic makeup of prostate cancer in addition to active mutations that are associated with the disease can help define a patient’s disease, George continues. The phenotype, patterns of the disease, and molecular uptake on PET imaging can all help clinicians understand which tumors are responsive to specific therapies, George concludes.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD